Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients

Projektinformationen

ImMoRiSt

ID Finanzhilfevereinbarung: 710079

DOI

10.3030/710079

Projekt abgeschlossen

EK-Unterschriftsdatum 11 Dezember 2015

Startdatum 1 Februar 2016

Enddatum 31 Juli 2016

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

LOPHIUS BIOSCIENCES GMBH
Germany

Periodic Reporting for period 1 - ImMoRiSt (Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients)

Berichtszeitraum: 2016-02-01 bis 2016-07-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Every year ~ 40.000 patients throughout the EU are transplanted with a solid organ e.g. kidney, lung, liver, heart or receive a stem cell transplantation (SCT). Adequate and personalized treatment of the severe and in part life threatening clinical complications is impeded by the lack of appropriate diagnostic tests that help physicians to ascertain the exact dosage of immunosuppressive drugs and identify patients an increased risk for transplantation related complications. This is mandatory to avoid organ rejection and to diminish clinical complications caused by infections.

Lophius Biosciences GmbH has developed innovative immune monitoring tools, the so called “I-Scan” products providing important information on the strength and functional impairment of the cellular immune system in all groups of transplant (solid organ and stem cell) recipients within 24 h. The “I-Scans” diagnostics combine proprietary stimulants (either T activated® antigens of pathogens (applied in T-Track® CMV) or a cocktail of cell-type specific stimulants (T-Track® ImmunoScan)) with a highly sensitive readout method (IFN- ELISpot).

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Both assay formats are based on Lophius’ proprietary “T-activation® technology” enabling a highly sensitive qualitative and quantitative measurement of cell-mediated immune function. The feasibility study performed during Phase 1 explored both, the clinical biomarker validation study and the best market entry strategy for two variant immune monitoring tools – the T-Track® CMV and the T-Track® ImmunoScan.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

A key outcome of the ImMoRiSt feasibility study was that stem cell transplantation (SCT) is the therapeutic area better suited as SOT to clinically validate and commercialize Lophius’ I-Scan IVD tests. Together with the study partners identified during the feasibility study Lophius will submit a Phase 2 application in the topic SMEInst-05-2016-2017: supporting innovative SMEs in the healthcare biotechnology sector, that includes the challenge “Clinical research for the validation of biomarkers and/or diagnostic medical devices”.

The clinical validation of a selected I-Scan product which is planned for Phase two of this innovation project will demonstrate that functional immune monitoring of a network of clinically relevant effector cells of the innate and adaptive immune system will substantially improve the outcome and aftercare of SCT recipients.

Main Contractor